The government may soon lift restrictions on some peptide treatments
NPR • • business
Key Points:
- The U.S. government may soon ease restrictions on certain unapproved peptide therapies, such as BPC-157, ipamorelin, and MOTS-c, which are currently prohibited by the FDA from being compounded by pharmacies.
- Proponents, including Health Secretary Robert F. Kennedy Jr., argue that lifting restrictions would reduce reliance on unsafe, unregulated overseas suppliers and provide access to peptides from ethical sources.
- Experts caution that most peptides lack evidence from rigorous human trials, raising concerns about their safety and potential harmful effects on organs or immune responses.
- Some clinicians, like Dr. Edwin Lee, advocate for peptides based on limited studies and claim drug companies avoid large trials due to patent issues, likening peptide use to early-stage medical innovation.
- The FDA has not announced a timeline for reclassification, and experts emphasize the need for regulation to prevent black market proliferation and protect consumers.
